PLASMA Act

Legislative and regulatory issues related to gene therapies for hemophilia B; Issues related to plasma and plasma derived therapies; Issues related to H.R. 6465/S. 4741 - Preserving Life-saving Access to Specialty Medicines in America Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Rx pricing; Issues related to plasma and plasma derived therapies; Issues related to H.R. 6465/S. 4741 - Preserving Life-saving Access to Specialty Medicines in America Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Rx pricing; Issues related to plasma and plasma derived therapies; Issues related to H.R. 6465/S. 4741 - Preserving Life-saving Access to Specialty Medicines in America Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2941/S.1332, Recognizing the Role of Direct Support Professionals Act, all provisions H.R. 2965/S.1333, Autism Family Caregivers Act of 2023, all provisions H.R. 3380, HEADs UP Act of 2023, all provisions H.R. 5408/S.2767, SSI Savings Penalty Elimination Act, all provisions H.R. 5893, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024, provisions related to funding for Kevin and Avontes Law H.R. 5894, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs and special education at the Department of Education H.R. 7213/S.4762, Autism CARES Act of 2024, all provisions H.R. 7300, Family-to-Family Reauthorization Act of 2024, all provisions H.R. 8774, Department of Defense Appropriations Act, 2025, provisions related to the congressionally directed medical research autism research program H.R. 9026, Making appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2025, and for other purposes, provisions related to funding for Kevin and Avontes Law H.R. 9028, Making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2025, and for other purposes, a proposal for research at the Department of Housing and Urban Development on autism and housing H.R. 9029, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2025, and for other purposes, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs, vocational rehabilitation, and special education programs at the Department of Education S. 4539/H.R. 9614, ENABLE Act, all provisions S.4921 - Department of Defense Appropriations Act, 2025, provisions related to the congressionally directed medical research autism research program S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs, vocational rehabilitation and special education programs at the Department of Education S.4796 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2025 a provision related to research at the Department of Housing and Urban Development on autism and housing S. 3076, Disability Employment Incentive Act, all provisions S. 2522/H.R. 5102, ABLE Match Act, all provisions S. 4910, ABLE Awareness Act, all provisions S. 4911, ABLE Employment Flexibility Act, all provisions S. 3528, Supporting Disabled Entrepreneurs Act, all provisions H.R. 2706/S. 1183, CharlotteWoodwardOrgan Transplant Discrimination Prevention Act, all provisions H.R. 670/S. 4741, ThinkDifferentlyDatabase Act, all provisions S. 5070, The Ensuring Access to Medicaid Buy-In Programs Act, all provisions S.5378, EASE with 211 Act, all provisions H.R.10296, ABLE Tomorrow Act, all provisions H.R. 6655, A Stronger Workforce for America Act, provisions related to improving employment opportunities for people with disabilities Advocacy with the Department of Health and Human Services, Food and Drug Administration, and Office of Management and Budget related to electrical stimulation devices A proposal for the creation of an Office of Caregiver Health at the Department of Health and Human Services A bill not yet introduced to enhance incentives to create accessible and inclusive workplaces

H.R. 2941/S.1332, Recognizing the Role of Direct Support Professionals Act, all provisions H.R. 2965/S.1333, Autism Family Caregivers Act of 2023, all provisions H.R. 3380, HEADs UP Act of 2023, all provisions H.R. 5408/S.2767, SSI Savings Penalty Elimination Act, all provisions H.R. 5893, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024, provisions related to funding for Kevin and Avontes Law H.R. 5894, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs and special education at the Department of Education H.R. 7213/S.4762, Autism CARES Act of 2024, all provisions H.R. 7300, Family-to-Family Reauthorization Act of 2024, all provisions H.R. 8774, Department of Defense Appropriations Act, 2025, provisions related to the congressionally directed medical research autism research program H.R. 9026, Making appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2025, and for other purposes, provisions related to funding for Kevin and Avontes Law H.R. 9028, Making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2025, and for other purposes, a proposal for research at the Department of Housing and Urban Development on autism and housing H.R. 9029, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2025, and for other purposes, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs, vocational rehabilitation, and special education programs at the Department of Education S. 4539/H.R. 9614, ENABLE Act, all provisions S.4921 - Department of Defense Appropriations Act, 2025, provisions related to the congressionally directed medical research autism research program S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs, vocational rehabilitation and special education programs at the Department of Education S.4796 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2025 a provision related to research at the Department of Housing and Urban Development on autism and housing S. 3076, Disability Employment Incentive Act, all provisions S. 2522/H.R. 5102, ABLE Match Act, all provisions S. 4910, ABLE Awareness Act, all provisions S. 4911, ABLE Employment Flexibility Act, all provisions S. 3528, Supporting Disabled Entrepreneurs Act, all provisions H.R. 2706/S. 1183, CharlotteWoodwardOrgan Transplant Discrimination Prevention Act, all provisions H.R. 670/S. 4741, ThinkDifferentlyDatabase Act, all provisions S. 5070, The Ensuring Access to Medicaid Buy-In Programs Act, all provisions S.5378, EASE with 211 Act, all provisions H.R.10296, ABLE Tomorrow Act, all provisions H.R. 6655, A Stronger Workforce for America Act, provisions related to improving employment opportunities for people with disabilities Advocacy with the Department of Health and Human Services, Food and Drug Administration, and Office of Management and Budget related to electrical stimulation devices A proposal for the creation of an Office of Caregiver Health at the Department of Health and Human Services A bill not yet introduced to enhance incentives to create accessible and inclusive workplaces

340B Program/Transparency; generics access; Clinical Trial Diversity S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S. 127 - Pharmacy Benefit Manager Transparency Act of 2023 To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. Sponsor: Sen. Cantwell, Maria [D-WA] S. 148 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Amy Klobuchar (D-MN) S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R. 9070, Affordable Prescriptions for Patients Act of 2024 To amend title 35, United States Code, to prohibit product hopping, and for other purposes. Sponsor: Rep. Issa, Darrell [R-CA-48] S. 150 - Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] H.R.6094 - Providing Realistic Opportunity To Equal and Comparable Treatment (PROTECT) for Rare Act To amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to refine the set of information sources for determining coverage of certain drugs and biologicals used in the treatment or management of a rare disease or condition, and for other purposes. Sponsor: Rep. Matsui, Doris O. [D-CA-7] S. 142 - Preserve Access to Affordable Generics and Biosimilars Act To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.2666 - EPCS 2.0 Act To amend the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to provide for requirements for electronic-prescribing for controlled substances under group health plans and group and individual health insurance coverage. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.7312 - EPCS 2.0 Act To provide for requirements for electronic-prescribing for controlled substances under group health plans and group and individual health insurance coverage. Sponsor: Rep. Kuster, Ann M. [D-NH-2] S.4741 - PLASMA Act To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program. Sponsor: Sen. Tillis, Thomas [R-NC] HR 6465 PLASMA Act To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program. Sponsor: Rep. Hudson, Richard [R-NC-9] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] H.R.1359 - Modernizing Opioid Treatment Access Act To expand the take-home prescribing of methadone through pharmacies. Sponsor: Rep. Norcross, Donald [D-NJ-1] S.644 - Modernizing Opioid Treatment Access Act To expand the take-home prescribing of methadone through pharmacies. Sponsor: Sen. Markey, Edward J. [D-MA]

340B Program/Transparency; generics access; Clinical Trial Diversity S. 1114, Expanding Access to Low-Cost Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to the 180-day exclusivity period. Sponsor: Sen. Smith, Tina [D-MN] S. 2305 - Biosimilar Red Tape Elimination Act To improve the requirements for making a determination of interchangeability of a biological product and its reference product. Sponsor: Sen. Lee, Mike [R-UT] S. 127 - Pharmacy Benefit Manager Transparency Act of 2023 To prevent unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs, and for other purposes. Sponsor: Sen. Cantwell, Maria [D-WA] S. 148 - Stop STALLING Act A bill to enable the Federal Trade Commission to deter filing of sham citizen petitions to cover an attempt to interfere with approval of a competing generic drug or biosimilar, to foster competition, and facilitate the efficient review of petitions filed in good faith to raise legitimate public health concerns, and for other purposes. Sponsor: Sen. Amy Klobuchar (D-MN) S.1339 - Pharmacy Benefit Manager Reform Act To provide for increased oversight of entities that provide pharmacy benefit management services on behalf of group health plans and health insurance coverage. Sponsor: Sen. Sanders, Bernard [I-VT] S. 775, Increasing Transparency in Generic Drug Applications To provide for increased transparency in generic drug applications. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.3839 - To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. Sponsor: Rep. Dunn, Neal P. [R-FL-2] H.R. 9070, Affordable Prescriptions for Patients Act of 2024 To amend title 35, United States Code, to prohibit product hopping, and for other purposes. Sponsor: Rep. Issa, Darrell [R-CA-48] S. 150 - Affordable Prescriptions for Patients Act of 2023 To amend the Federal Trade Commission Act to prohibit product hopping, and for other purposes. Sponsor: Sen. Cornyn, John [R-TX] S.1542, DRUG Act To improve services provided by pharmacy benefit managers. Sponsor: Sen. Marshall, Roger [R-KS] H.R.6094 - Providing Realistic Opportunity To Equal and Comparable Treatment (PROTECT) for Rare Act To amend titles XVIII and XIX of the Social Security Act and title XXVII of the Public Health Service Act to refine the set of information sources for determining coverage of certain drugs and biologicals used in the treatment or management of a rare disease or condition, and for other purposes. Sponsor: Rep. Matsui, Doris O. [D-CA-7] S. 142 - Preserve Access to Affordable Generics and Biosimilars Act To prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market, and to prohibit biological product manufacturers from compensating biosimilar and interchangeable companies to delay the entry of biosimilar biological products and interchangeable biological products. Sponsor: Sen. Klobuchar, Amy [D-MN] S.2666 - EPCS 2.0 Act To amend the Public Health Service Act, the Employee Retirement Income Security Act of 1974, and the Internal Revenue Code of 1986 to provide for requirements for electronic-prescribing for controlled substances under group health plans and group and individual health insurance coverage. Sponsor: Sen. Hassan, Margaret Wood [D-NH] H.R.7312 - EPCS 2.0 Act To provide for requirements for electronic-prescribing for controlled substances under group health plans and group and individual health insurance coverage. Sponsor: Rep. Kuster, Ann M. [D-NH-2] S.4741 - PLASMA Act To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program. Sponsor: Sen. Tillis, Thomas [R-NC] HR 6465 PLASMA Act To amend title XVIII of the Social Security Act to provide a phase-in for plasma-derived products under the manufacturer discount program. Sponsor: Rep. Hudson, Richard [R-NC-9] S. 1067, Ensuring Timely Access to Generics Act To amend the Federal Food, Drug, and Cosmetic Act with respect to citizen petitions. Sponsor: Sen. Shaheen, Jeanne [D-NH] H.R.1359 - Modernizing Opioid Treatment Access Act To expand the take-home prescribing of methadone through pharmacies. Sponsor: Rep. Norcross, Donald [D-NJ-1] S.644 - Modernizing Opioid Treatment Access Act To expand the take-home prescribing of methadone through pharmacies. Sponsor: Sen. Markey, Edward J. [D-MA]

Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741, 118th Congress).

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to plasma therapies. H.R. 6465 / S.4741, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. H.R. 2666, the Medicaid VBPs for Patients (MVP) Act and issues related to value-based payments. Issues related to drug shortages. Issues related to the Medicaid Drug Rebate Program. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Monitored issues related to pharmacy benefit management.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

PLASMA Act (S.4741/H.R.6465)

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 2941/S.1332, Recognizing the Role of Direct Support Professionals Act, all provisions H.R. 2965/S.1333, Autism Family Caregivers Act of 2023, all provisions H.R. 3380, HEADs UP Act of 2023, all provisions H.R. 5408/S.2767, SSI Savings Penalty Elimination Act, all provisions H.R. 5893, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024, provisions related to funding for Kevin and Avontes Law H.R. 5894, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs and special education at the Department of Education H.R. 6468, Ban Water Beads Act, all provisions H.R. 7213/S.4762, Autism CARES Act of 2024, all provisions H.R. 7300, Family-to-Family Reauthorization Act of 2024, all provisions H.R. 8018/S.3109, Alleviating Barriers for Caregivers Act, all provisions H.R. 8774, Department of Defense Appropriations Act, 2025, provisions related to the congressionally directed medical research autism research program H.R. 9026, Making appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2025, and for other purposes, provisions related to funding for Kevin and Avontes Law H.R. 9027, Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2025, and for other purposes, a proposal to limit the Food and Drug Administration's ability to restrict certain uses of a device under certain circumstances H.R. 9028, Making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2025, and for other purposes, a proposal for research at the Department of Housing and Urban Development on autism and housing H.R. 9029, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2025, and for other purposes, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs, vocational rehabilitation, and special education programs at the Department of Education S. 4298, Esthers Law, all provisions S. 4539/H.R. 9614, ENABLE Act, all provisions H.R.9436 - SPECTRUM Act, all provisions S.4921 - Department of Defense Appropriations Act, 2025, provisions related to the congressionally directed medical research autism research program S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs, vocational rehabilitation and special education programs at the Department of Education S.4796 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2025 a proposal for research at the Department of Housing and Urban Development on autism and housing S. 3076, Disability Employment Incentive Act, all provisions S. 2522/H.R. 5102, ABLE Match Act, all provisions S. 4910, ABLE Awareness Act, all provisions S. 4911, ABLE Employment Flexibility Act, all provisions S. 3528, Supporting Disabled Entrepreneurs Act, all provisions H.R. 2706/S. 1183, Charlotte Woodward Organ Transplant Discrimination Prevention Act, all provisions H.R. 670/S. 4741, Think Differently Database Act, all provisions A proposal for the creation of an Office of Caregiver Health at the Department of Health and Human Services A bill not yet introduced to enhance incentives to create accessible and inclusive workplaces

H.R. 2941/S.1332, Recognizing the Role of Direct Support Professionals Act, all provisions H.R. 2965/S.1333, Autism Family Caregivers Act of 2023, all provisions H.R. 3380, HEADs UP Act of 2023, all provisions H.R. 5408/S.2767, SSI Savings Penalty Elimination Act, all provisions H.R. 5893, Commerce, Justice, Science, and Related Agencies Appropriations Act, 2024, provisions related to funding for Kevin and Avontes Law H.R. 5894, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2024, and for other purposes, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs and special education at the Department of Education H.R. 6468, Ban Water Beads Act, all provisions H.R. 7213/S.4762, Autism CARES Act of 2024, all provisions H.R. 7300, Family-to-Family Reauthorization Act of 2024, all provisions H.R. 8018/S.3109, Alleviating Barriers for Caregivers Act, all provisions H.R. 8774, Department of Defense Appropriations Act, 2025, provisions related to the congressionally directed medical research autism research program H.R. 9026, Making appropriations for the Departments of Commerce and Justice, Science, and Related Agencies for the fiscal year ending September 30, 2025, and for other purposes, provisions related to funding for Kevin and Avontes Law H.R. 9027, Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 2025, and for other purposes, a proposal to limit the Food and Drug Administration's ability to restrict certain uses of a device under certain circumstances H.R. 9028, Making appropriations for the Departments of Transportation, and Housing and Urban Development, and related agencies for the fiscal year ending September 30, 2025, and for other purposes, a proposal for research at the Department of Housing and Urban Development on autism and housing H.R. 9029, Making appropriations for the Departments of Labor, Health and Human Services, and Education, and related agencies for the fiscal year ending September 30, 2025, and for other purposes, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs, vocational rehabilitation, and special education programs at the Department of Education S. 4298, Esthers Law, all provisions S. 4539/H.R. 9614, ENABLE Act, all provisions H.R.9436 - SPECTRUM Act, all provisions S.4921 - Department of Defense Appropriations Act, 2025, provisions related to the congressionally directed medical research autism research program S.4942 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025, provisions related to funding autism research and services at the National Institutes of Health, Centers for Disease Control and Prevention, Health Resources and Services Administration; assistive technology programs, vocational rehabilitation and special education programs at the Department of Education S.4796 - Transportation, Housing and Urban Development, and Related Agencies Appropriations Act, 2025 a proposal for research at the Department of Housing and Urban Development on autism and housing S. 3076, Disability Employment Incentive Act, all provisions S. 2522/H.R. 5102, ABLE Match Act, all provisions S. 4910, ABLE Awareness Act, all provisions S. 4911, ABLE Employment Flexibility Act, all provisions S. 3528, Supporting Disabled Entrepreneurs Act, all provisions H.R. 2706/S. 1183, Charlotte Woodward Organ Transplant Discrimination Prevention Act, all provisions H.R. 670/S. 4741, Think Differently Database Act, all provisions A proposal for the creation of an Office of Caregiver Health at the Department of Health and Human Services A bill not yet introduced to enhance incentives to create accessible and inclusive workplaces

Issues related to the implementation of the Inflation Reduction Act of 2022 (PL 117-169); Issues related to Rx pricing. Issues related to plasma and plasma derived therapies. Issues related to H.R. 6465/S.4741 - Preserving Life-saving Access to Specialty Medicines in America Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to legislative and regulatory issues related to gene therapies for hemophilia B. Issues related to plasma and plasma derived therapies. Issues related to H.R. 6465/S.4741 - Preserving Life-saving Access to Specialty Medicines in America Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to Rx pricing. Issues related to plasma and plasma derived therapies. Issues related to H.R. 6465/S.4741 - Preserving Life-saving Access to Specialty Medicines in America Act.

Client expense: Not reported · Firm income: $60,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to access to plasma-derived products and implementation of the Inflation Reduction Act (IRA, P. L. 117-169), including the Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act (H.R. 6465 / S. 4741).

Client expense: Not reported · Firm income: $70,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE